SCHEMBL3010469

SCHEMBL3010469

Cc1cc(C)c(C)c(S(=O)(=O)N2CCN(c3nc(-c4ccccc4)cs3)CC2)c1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.67
LMNA P02545 4/20 0.67
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
RAB9A P51151 6/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
ALDH1A1 P00352 4/20 0.55
NPC1 O15118 4/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
AR P10275 3/20 0.53
HSD17B10 Q99714 3/20 0.53
TP53 P04637 2/20 0.53
ALOX15 P16050 1/20 0.53
MAPT P10636 5/20 0.53
HTT P42858 3/20 0.53
RECQL P46063 2/20 0.53
KDM4E B2RXH2 1/20 0.53
USP2 O75604 1/20 0.52
GAA P10253 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652514 0.94 MAPK1 (0.60) MAPK1LMNAMEN1KMT2ARAB9A
SCHEMBL3019906 0.91 SMN1; SMN2 (0.57) MAPK1LMNAMEN1KMT2ARAB9A
SCHEMBL3016434 0.90 MEN1 (0.55) MAPK1LMNAMEN1KMT2ARAB9A
SCHEMBL3016103 0.89 MAPT (0.56) MAPK1LMNAMEN1KMT2ARAB9A
SCHEMBL3012842 0.89 MAPK1 (0.67) MAPK1LMNAMEN1KMT2ARAB9A
SCHEMBL3650189 0.89 MEN1 (0.53) MAPK1LMNAMEN1KMT2ARAB9A
SCHEMBL3021719 0.88 MEN1 (0.51) MAPK1LMNAMEN1KMT2ARAB9A
SCHEMBL3011184 0.88 SMN1; SMN2 (0.54) MAPK1LMNAMEN1KMT2ARAB9A
SCHEMBL3001675 0.88 MEN1 (0.50) MAPK1LMNAMEN1KMT2ARAB9A
SCHEMBL3017991 0.87 LMNA (0.56) MAPK1LMNAMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPK1 2767/4885LMNA 80/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.